Related Experiment Videos
Long-standing malignant pancreatic carcinoid treated with octreotide
1Unidad de Ecoendoscopia y Eco-Doppler, Centro Médico Teknon, Barcelona, Spain. varas@dr.teknon.es
Revista Espanola De Enfermedades Digestivas
|December 15, 2010
Summary
A rare case of malignant pancreatic carcinoid with carcinoid syndrome was successfully treated, achieving 12-year survival. This study reviews the literature on this unusual neuroendocrine tumor presentation.
Area of Science:
- Oncology
- Endocrinology
- Gastroenterology
Background:
- Malignant pancreatic carcinoids are rare neuroendocrine tumors.
- Carcinoid syndrome results from hormone hypersecretion, often serotonin.
- Metastatic disease presents significant treatment challenges.
Observation:
- A male patient presented with metastatic, serotonin-secreting pancreatic carcinoid.
- Diagnostic imaging included ultrasound, CT, MRI, EUS, and Octreoscan.
- The patient exhibited carcinoid-like syndrome due to high urinary 5-HIAA levels.
Findings:
- The patient received a multimodal treatment regimen: chemotherapy, interferon, and octreotide.
- Long-term survival of 12 years was achieved post-diagnosis.
- This represents the second reported case in the country, highlighting its rarity.
Implications:
- Aggressive treatment strategies can lead to prolonged survival in metastatic pancreatic carcinoids.
- This case underscores the importance of comprehensive diagnostic workups for rare neuroendocrine tumors.
- Further research into optimal treatment protocols for such rare malignancies is warranted.
